Index - P/E - EPS (ttm) -2.78 Insider Own 76.37% Shs Outstand 27.61M Perf Week 3.96%
Market Cap 38.76M Forward P/E - EPS next Y -0.96 Insider Trans 1.73% Shs Float 8.72M Perf Month -19.23%
Income -76.40M PEG - EPS next Q -0.11 Inst Own 15.88% Short Float 4.35% Perf Quarter 56.72%
Sales 0.00M P/S - EPS this Y 46.94% Inst Trans -4.73% Short Ratio 0.31 Perf Half Y -52.05%
Book/sh 1.33 P/B 0.79 EPS next Y 34.58% ROA -76.37% Short Interest 0.38M Perf Year -67.08%
Cash/sh 1.21 P/C 0.87 EPS next 5Y - ROE -107.25% 52W Range 0.49 - 3.25 Perf YTD 90.91%
Dividend Est. - P/FCF - EPS past 5Y -44.91% ROI -169.90% 52W High -67.69% Beta -0.09
Dividend TTM - Quick Ratio 3.02 Sales past 5Y 0.00% Gross Margin - 52W Low 114.29% ATR (14) 0.15
Dividend Ex-Date - Current Ratio 3.02 EPS Y/Y TTM 13.71% Oper. Margin 0.00% RSI (14) 48.44 Volatility 9.84% 12.28%
Employees 73 Debt/Eq 0.34 Sales Y/Y TTM - Profit Margin - Recom 1.50 Target Price 5.50
Option/Short No / Yes LT Debt/Eq 0.22 EPS Q/Q 21.81% Payout - Rel Volume 0.15 Prev Close 1.08
Sales Surprise - EPS Surprise -2.81% Sales Q/Q - Earnings Apr 01 AMC Avg Volume 1.23M Price 1.05
SMA20 -11.39% SMA50 11.70% SMA200 -30.04% Trades
Volume 182,804 Change -2.78%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-21-22 Initiated Chardan Capital Markets
Buy
$7
Jan-10-22 Initiated H.C. Wainwright
Buy
$36
Nov-16-21 Initiated Raymond James
Outperform
$31
Nov-16-21 Initiated Morgan Stanley
Overweight
$32
Nov-16-21 Initiated Guggenheim
Buy
$40
Nov-16-21 Initiated Cowen
Outperform
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
Loading…
07:00AM
06:45AM
Feb-28-24 04:01PM
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
08:30AM
Loading…
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
(Thomson Reuters StreetEvents)
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
07:30AM
Loading…
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 733 469 2,019,563 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 267 171 734,546 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 1,540 1,278 2,020,296 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 560 465 734,813 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 1,566 1,362 2,021,836 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 569 495 735,373 Jan 16 06:16 PM
Index - P/E - EPS (ttm) - Insider Own 29.61% Shs Outstand 43.12M Perf Week -5.71%
Market Cap 648.09M Forward P/E - EPS next Y -4.00 Insider Trans 19.27% Shs Float 30.35M Perf Month -31.43%
Income - PEG - EPS next Q -0.84 Inst Own 3.27% Short Float 5.13% Perf Quarter -
Sales - P/S - EPS this Y 96.35% Inst Trans - Short Ratio 3.08 Perf Half Y -
Book/sh -3.05 P/B - EPS next Y -22.14% ROA - Short Interest 1.56M Perf Year -
Cash/sh 1.33 P/C 11.26 EPS next 5Y - ROE - 52W Range 13.96 - 35.06 Perf YTD -49.90%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -57.13% Beta -
Dividend TTM - Quick Ratio 3.05 Sales past 5Y -37.90% Gross Margin - 52W Low 7.66% ATR (14) 1.58
Dividend Ex-Date - Current Ratio 3.05 EPS Y/Y TTM - Oper. Margin - RSI (14) 29.08 Volatility 9.90% 7.83%
Employees 96 Debt/Eq 0.18 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 42.75
Option/Short Yes / Yes LT Debt/Eq 0.13 EPS Q/Q - Payout - Rel Volume 1.07 Prev Close 16.61
Sales Surprise - EPS Surprise -2819.81% Sales Q/Q - Earnings Mar 26 AMC Avg Volume 504.48K Price 15.03
SMA20 -25.09% SMA50 -37.79% SMA200 -39.68% Trades
Volume 538,183 Change -9.51%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-04-24 Initiated Wells Fargo
Overweight
$44
Mar-04-24 Initiated Morgan Stanley
Overweight
$40
Mar-04-24 Initiated Leerink Partners
Outperform
$48
Mar-04-24 Initiated JP Morgan
Overweight
$39
Apr-11-24 05:01PM
Mar-29-24 02:59PM
Mar-26-24 04:05PM
Mar-14-24 07:00AM
(The Wall Street Journal)
Mar-07-24 07:26PM
06:14PM
Loading…
06:14PM
Feb-12-24 04:39PM
Feb-07-24 10:29PM
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Feb 12 '24 Buy 22.00 910,000 20,020,000 4,126,119 Feb 13 05:48 PM Northpond Ventures III GP, LLC Former 10% Owner Feb 12 '24 Buy 22.00 450,000 9,900,000 450,000 Feb 12 05:51 PM Bain Capital Life Sciences Inv 10% Owner Feb 12 '24 Buy 22.00 450,000 9,900,000 3,163,868 Feb 14 05:26 PM Vida Ventures, LLC 10% Owner Feb 12 '24 Buy 22.00 253,136 5,568,992 252,553 Feb 14 07:04 PM
Index RUT P/E - EPS (ttm) -4.15 Insider Own 47.91% Shs Outstand 75.50M Perf Week 5.23%
Market Cap 1.41B Forward P/E - EPS next Y -4.26 Insider Trans 53.01% Shs Float 47.38M Perf Month -12.38%
Income -307.00M PEG - EPS next Q -1.01 Inst Own 53.95% Short Float 14.44% Perf Quarter -2.21%
Sales 117.00M P/S 12.05 EPS this Y 6.66% Inst Trans -0.67% Short Ratio 8.82 Perf Half Y -1.34%
Book/sh 6.12 P/B 2.53 EPS next Y -9.91% ROA -25.16% Short Interest 6.84M Perf Year -13.12%
Cash/sh 8.35 P/C 1.86 EPS next 5Y - ROE -54.87% 52W Range 12.95 - 25.47 Perf YTD -18.85%
Dividend Est. - P/FCF - EPS past 5Y -23.70% ROI -53.67% 52W High -39.14% Beta 0.87
Dividend TTM - Quick Ratio 4.52 Sales past 5Y 164.80% Gross Margin 86.32% 52W Low 19.69% ATR (14) 0.87
Dividend Ex-Date - Current Ratio 4.52 EPS Y/Y TTM -11.90% Oper. Margin -290.60% RSI (14) 44.60 Volatility 5.38% 5.42%
Employees 577 Debt/Eq 0.26 Sales Y/Y TTM 4.46% Profit Margin -262.39% Recom 1.42 Target Price 38.50
Option/Short Yes / Yes LT Debt/Eq 0.24 EPS Q/Q -16.23% Payout - Rel Volume 0.59 Prev Close 15.50
Sales Surprise 9.54% EPS Surprise -5.41% Sales Q/Q -7.89% Earnings May 08 AMC Avg Volume 775.44K Price 15.50
SMA20 -2.61% SMA50 -10.71% SMA200 -11.00% Trades
Volume 455,120 Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-18-22 Initiated BofA Securities
Neutral
$33
Oct-11-22 Initiated Morgan Stanley
Overweight
$40
Oct-15-21 Resumed BTIG Research
Buy
$57
Nov-24-20 Initiated Berenberg
Buy
$50
Nov-23-20 Initiated Evercore ISI
Outperform
Apr-03-20 Initiated Cantor Fitzgerald
Overweight
$21
Mar-04-20 Initiated Barclays
Overweight
$24
Nov-12-19 Initiated SunTrust
Buy
$20
Sep-27-19 Initiated Mizuho
Buy
$22
May-24-19 Resumed Citigroup
Buy
$25
Oct-09-18 Initiated Wedbush
Outperform
$22
Apr-09-18 Initiated Leerink Partners
Outperform
$21
Apr-09-18 Initiated Goldman
Neutral
$18
Apr-09-18 Initiated Citigroup
Buy
$18
Show Previous Ratings
May-02-24 04:05PM
May-01-24 10:01AM
Apr-24-24 04:00PM
Apr-23-24 04:05PM
Apr-09-24 04:35PM
07:01PM
Loading…
Mar-29-24 07:01PM
Mar-26-24 04:35PM
Mar-20-24 07:00PM
Mar-11-24 04:35PM
Feb-29-24 03:14AM
Feb-28-24 04:05PM
Feb-27-24 04:35PM
Feb-22-24 11:10AM
09:55AM
07:16AM
(Thomson Reuters StreetEvents)
04:37PM
Loading…
Feb-21-24 04:37PM
04:05PM
Feb-09-24 04:35PM
Feb-07-24 05:00PM
Feb-05-24 12:59PM
Jan-29-24 05:00PM
Jan-26-24 04:35PM
Jan-16-24 05:00PM
Dec-11-23 04:35PM
Dec-04-23 08:00AM
Nov-27-23 04:35PM
Nov-14-23 04:00PM
Nov-13-23 04:35PM
Nov-08-23 04:05PM
Nov-07-23 04:01PM
05:00PM
Loading…
Nov-06-23 05:00PM
Oct-31-23 10:01AM
Oct-24-23 04:35PM
Oct-17-23 04:00PM
Oct-10-23 04:35PM
Sep-27-23 05:14AM
Sep-26-23 04:35PM
Sep-11-23 04:35PM
Sep-05-23 07:37PM
Aug-24-23 04:35PM
11:30AM
09:02AM
Aug-23-23 11:39AM
09:00AM
Aug-09-23 04:35PM
Aug-07-23 09:15AM
08:00AM
Aug-03-23 05:55PM
Aug-02-23 05:25PM
Aug-01-23 05:45PM
Jul-25-23 04:35PM
Jul-11-23 04:35PM
Jul-03-23 06:50AM
Jun-26-23 04:35PM
Jun-21-23 08:00PM
Jun-12-23 12:08PM
Jun-09-23 04:35PM
Jun-05-23 02:59PM
Jun-03-23 01:30PM
May-30-23 04:00PM
May-26-23 04:05PM
(Investor's Business Daily) +25.89%
10:27AM
(Investor's Business Daily)
May-24-23 04:35PM
May-17-23 08:30AM
May-16-23 11:51AM
09:31AM
May-15-23 08:30AM
May-11-23 09:44AM
09:33AM
07:44AM
May-09-23 06:15PM
04:05PM
May-08-23 04:35PM
10:04AM
May-05-23 12:45PM
09:17AM
May-04-23 12:04PM
May-03-23 01:47PM
01:20PM
May-01-23 10:00AM
Apr-26-23 08:00PM
Apr-25-23 04:05PM
Apr-19-23 11:17AM
Apr-11-23 04:05PM
Mar-09-23 04:05PM
Mar-06-23 12:33PM
Mar-03-23 02:20PM
Mar-02-23 04:00PM
Feb-28-23 05:35PM
04:05PM
Feb-24-23 04:05PM
Feb-23-23 01:41PM
Feb-17-23 12:24PM
Feb-15-23 10:57AM
07:50AM
Feb-14-23 06:33AM
Feb-09-23 04:05PM
09:48AM
Feb-08-23 10:53AM
Feb-07-23 12:17PM
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Jarrett Jennifer Chief Operating Officer Mar 27 '24 Sale 17.55 11,551 202,720 215,253 Mar 29 04:20 PM Jarrett Jennifer Chief Operating Officer Mar 18 '24 Sale 17.92 13,449 240,941 226,804 Mar 20 04:19 PM Jarrett Jennifer Chief Operating Officer Feb 27 '24 Sale 20.11 34,070 685,148 240,253 Feb 28 07:55 PM Jaen Juan C. President Feb 27 '24 Sale 20.10 23,132 464,953 1,188,233 Feb 28 07:55 PM Jarrett Jennifer Chief Operating Officer Feb 26 '24 Sale 20.07 24,555 492,819 274,323 Feb 28 07:55 PM Jaen Juan C. President Feb 26 '24 Sale 20.06 3,900 78,234 1,211,365 Feb 28 07:55 PM GILEAD SCIENCES, INC. 10% Owner Jan 29 '24 Buy 21.00 15,238,095 319,999,995 30,061,124 Jan 31 05:00 PM Jaen Juan C. President Jan 02 '24 Sale 20.09 6,975 140,128 1,215,265 Jan 04 05:22 PM Goeltz II Robert C. Chief Financial Officer Jan 02 '24 Sale 20.00 2,004 40,080 51,831 Jan 04 05:23 PM Jarrett Jennifer Chief Operating Officer Dec 22 '23 Sale 17.76 21,521 382,213 258,878 Dec 26 04:04 PM Azoy Alexander Chief Accounting Officer Dec 01 '23 Sale 14.95 282 4,216 11,596 Dec 05 04:28 PM Jarrett Jennifer Chief Operating Officer Sep 22 '23 Sale 19.99 21,369 427,166 302,691 Sep 26 04:35 PM Jarrett Jennifer Chief Operating Officer Jul 28 '23 Sale 20.25 45,000 911,250 336,566 Jul 31 04:15 PM Azoy Alexander Chief Accounting Officer Jul 03 '23 Sale 20.41 1,018 20,777 11,596 Jul 05 04:05 PM GILEAD SCIENCES, INC. 10% Owner Jun 28 '23 Buy 19.26 1,010,000 19,452,600 14,823,029 Jun 30 03:12 PM Jarrett Jennifer Chief Operating Officer Jun 22 '23 Sale 19.12 12,437 237,795 381,566 Jun 26 04:36 PM Jarrett Jennifer Chief Operating Officer Jun 16 '23 Sale 19.35 12,563 243,094 394,003 Jun 16 08:16 PM Goeltz II Robert C. Chief Financial Officer Jun 07 '23 Sale 20.04 4,049 81,142 59,392 Jun 09 04:05 PM
Index RUT P/E - EPS (ttm) -1.83 Insider Own 49.91% Shs Outstand 113.97M Perf Week 0.81%
Market Cap 92.67M Forward P/E - EPS next Y -0.30 Insider Trans -0.30% Shs Float 57.56M Perf Month 5.07%
Income -190.42M PEG - EPS next Q -0.16 Inst Own 42.66% Short Float 11.12% Perf Quarter 4.74%
Sales 0.00M P/S - EPS this Y 77.21% Inst Trans 25.02% Short Ratio 10.66 Perf Half Y -46.23%
Book/sh 1.28 P/B 0.63 EPS next Y 28.87% ROA -81.40% Short Interest 6.40M Perf Year -78.32%
Cash/sh 1.60 P/C 0.50 EPS next 5Y - ROE -102.85% 52W Range 0.62 - 6.12 Perf YTD 18.64%
Dividend Est. - P/FCF - EPS past 5Y -70.96% ROI -117.23% 52W High -86.82% Beta 0.77
Dividend TTM - Quick Ratio 6.61 Sales past 5Y -37.09% Gross Margin - 52W Low 29.43% ATR (14) 0.04
Dividend Ex-Date - Current Ratio 6.61 EPS Y/Y TTM 19.73% Oper. Margin 0.00% RSI (14) 58.52 Volatility 3.97% 4.96%
Employees 112 Debt/Eq 0.19 Sales Y/Y TTM - Profit Margin - Recom 4.25 Target Price 0.83
Option/Short Yes / Yes LT Debt/Eq 0.11 EPS Q/Q -27.88% Payout - Rel Volume 0.25 Prev Close 0.81
Sales Surprise - EPS Surprise 6.07% Sales Q/Q - Earnings Nov 02 BMO Avg Volume 600.44K Price 0.81
SMA20 5.03% SMA50 7.25% SMA200 -49.90% Trades
Volume 147,464 Change -0.43%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-26-23 Downgrade BofA Securities
Buy → Underperform
$17 → $1
Dec-22-23 Downgrade Piper Sandler
Overweight → Neutral
Dec-22-23 Downgrade Leerink Partners
Outperform → Market Perform
Dec-22-23 Downgrade JP Morgan
Overweight → Underweight
Aug-18-23 Initiated BofA Securities
Buy
$17
Oct-19-21 Resumed Morgan Stanley
Overweight
$48
Aug-24-20 Initiated SVB Leerink
Outperform
$41
Aug-24-20 Initiated Morgan Stanley
Overweight
$49
Aug-24-20 Initiated JP Morgan
Overweight
$50
Mar-18-24 03:53PM
Mar-13-24 11:53AM
10:00AM
Mar-12-24 05:50AM
Mar-06-24 06:17PM
05:37PM
Loading…
Mar-04-24 05:37PM
Feb-28-24 01:06AM
Feb-27-24 08:00AM
Feb-26-24 12:27PM
Feb-23-24 10:30AM
Jan-29-24 09:40AM
Jan-24-24 09:45AM
Jan-12-24 09:35AM
Jan-05-24 11:03AM
08:37AM
10:04AM
Loading…
Dec-26-23 10:04AM
Dec-22-23 09:31AM
08:30AM
07:10AM
07:00AM
Dec-05-23 08:55AM
Nov-16-23 07:00AM
Nov-02-23 10:04AM
07:00AM
Sep-21-23 02:44PM
Sep-14-23 09:59AM
Aug-28-23 07:00AM
Aug-03-23 07:00AM
Jul-21-23 07:17AM
Jul-12-23 03:12AM
07:34AM
Loading…
Jul-04-23 07:34AM
Jul-03-23 03:59AM
Jun-27-23 12:00PM
Jun-23-23 01:56PM
Jun-21-23 09:20PM
04:18PM
Jun-09-23 11:04AM
Jun-05-23 07:00AM
May-16-23 07:00AM
May-04-23 07:00AM
May-01-23 07:00AM
Apr-26-23 05:12PM
07:00AM
Mar-30-23 11:12AM
Feb-23-23 04:15PM
Feb-15-23 10:05AM
07:07AM
07:00AM
Feb-10-23 09:55AM
Feb-07-23 10:17AM
Feb-01-23 07:00AM
Jan-25-23 12:00PM
09:55AM
09:40AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-10-22 05:15PM
Nov-15-22 07:00AM
Nov-03-22 09:07AM
07:00AM
Oct-21-22 08:30AM
Sep-06-22 09:55AM
Aug-31-22 07:00AM
Aug-19-22 09:55AM
Aug-04-22 07:00AM
Aug-03-22 09:55AM
Aug-01-22 08:09AM
Jul-27-22 07:00AM
Jun-07-22 12:07PM
08:30AM
May-05-22 07:00AM
Apr-21-22 11:35AM
Apr-20-22 07:00AM
Apr-04-22 07:40PM
Mar-31-22 07:00AM
Mar-23-22 09:56AM
Mar-22-22 07:00AM
Feb-11-22 07:00AM
Feb-10-22 07:00AM
Jan-05-22 07:30AM
Jan-03-22 04:05PM
Dec-16-21 04:05PM
Dec-11-21 01:00PM
Nov-17-21 11:57AM
Nov-15-21 07:00AM
Nov-10-21 11:48AM
Nov-05-21 07:00AM
Oct-29-21 09:47AM
Oct-06-21 11:31AM
Oct-05-21 06:48AM
Oct-04-21 07:00AM
Sep-29-21 02:09PM
07:00AM
Sep-07-21 07:00AM
Sep-03-21 08:19AM
Aug-26-21 01:41PM
Aug-06-21 07:00AM
Jun-27-21 03:19AM
May-06-21 07:00AM
Apr-07-21 09:45PM
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sinha Vikas See Remarks Apr 22 '24 Sale 0.75 1,857 1,393 1,138,096 Apr 23 04:15 PM Miller Edward General Counsel Apr 22 '24 Sale 0.75 757 568 223,227 Apr 23 04:15 PM Hagen Brett R Chief Accounting Officer Apr 22 '24 Sale 0.75 480 360 77,619 Apr 23 04:15 PM Brainard Diana Chief Executive Officer Apr 19 '24 Sale 0.75 9,601 7,207 802,935 Apr 23 04:15 PM Sinha Vikas See Remarks Apr 19 '24 Sale 0.75 1,521 1,142 1,139,953 Apr 23 04:15 PM Miller Edward General Counsel Apr 19 '24 Sale 0.75 626 470 223,984 Apr 23 04:15 PM Hagen Brett R Chief Accounting Officer Apr 19 '24 Sale 0.75 473 355 78,099 Apr 23 04:15 PM Brainard Diana Chief Executive Officer Apr 02 '24 Sale 0.77 1,533 1,183 812,536 Apr 04 04:15 PM Sinha Vikas See Remarks Apr 02 '24 Sale 0.77 885 683 1,141,474 Apr 04 04:15 PM Miller Edward General Counsel Apr 02 '24 Sale 0.77 368 284 224,610 Apr 04 04:15 PM Hagen Brett R Chief Accounting Officer Apr 02 '24 Sale 0.77 281 217 78,572 Apr 04 04:15 PM Brainard Diana Chief Executive Officer Feb 21 '24 Sale 0.71 5,155 3,650 814,069 Feb 22 04:18 PM Brainard Diana Chief Executive Officer Feb 20 '24 Sale 0.70 3,097 2,153 819,224 Feb 22 04:18 PM Sinha Vikas See Remarks Feb 20 '24 Sale 0.70 2,893 2,011 1,142,359 Feb 22 04:15 PM Hagen Brett R Chief Accounting Officer Feb 20 '24 Sale 0.70 494 343 78,853 Feb 22 04:15 PM Miller Edward General Counsel Feb 20 '24 Sale 0.70 385 268 224,978 Feb 22 04:16 PM Hagen Brett R Chief Accounting Officer Feb 08 '24 Sale 0.67 11,150 7,494 79,347 Feb 09 08:01 PM Brainard Diana Chief Executive Officer Feb 05 '24 Sale 0.67 41,421 27,752 822,321 Feb 06 04:38 PM Sinha Vikas See Remarks Feb 05 '24 Sale 0.67 18,331 12,282 1,145,252 Feb 06 04:46 PM Miller Edward General Counsel Feb 05 '24 Sale 0.67 8,869 5,942 225,363 Feb 06 04:40 PM Hagen Brett R Chief Accounting Officer Feb 05 '24 Sale 0.67 5,792 3,881 90,497 Feb 06 04:39 PM Brainard Diana Chief Executive Officer Jan 23 '24 Sale 0.67 9,500 6,369 863,742 Jan 25 04:15 PM Sinha Vikas See Remarks Jan 23 '24 Sale 0.67 3,205 2,150 1,163,583 Jan 25 04:15 PM Miller Edward General Counsel Jan 23 '24 Sale 0.67 1,302 873 234,232 Jan 25 04:15 PM Hagen Brett R Chief Accounting Officer Jan 23 '24 Sale 0.67 901 604 96,289 Jan 25 04:15 PM Brainard Diana Chief Executive Officer Jan 04 '24 Sale 0.64 1,664 1,063 873,242 Jan 08 04:15 PM Sinha Vikas See Remarks Jan 04 '24 Sale 0.64 961 614 1,166,788 Jan 08 04:15 PM Miller Edward General Counsel Jan 04 '24 Sale 0.64 424 271 235,534 Jan 08 04:15 PM Hagen Brett R Chief Accounting Officer Jan 04 '24 Sale 0.64 310 198 97,190 Jan 08 04:15 PM Hagen Brett R Chief Accounting Officer Dec 27 '23 Sale 0.74 28,335 20,838 97,500 Jan 02 07:36 PM Brainard Diana Chief Executive Officer Nov 20 '23 Sale 1.69 4,382 7,408 874,906 Nov 21 05:00 PM Brainard Diana Chief Executive Officer Nov 17 '23 Sale 1.63 2,689 4,386 879,288 Nov 21 05:00 PM Sinha Vikas See Remarks Nov 17 '23 Sale 1.63 2,490 4,061 1,167,749 Nov 21 05:00 PM Hagen Brett R Chief Accounting Officer Nov 17 '23 Sale 1.63 403 657 125,835 Nov 21 05:00 PM Sinha Vikas See Remarks Oct 20 '23 Sale 1.54 1,475 2,273 1,170,239 Oct 23 05:00 PM Hagen Brett R Chief Accounting Officer Oct 20 '23 Sale 1.54 357 550 126,238 Oct 23 05:00 PM Brainard Diana Chief Executive Officer Oct 19 '23 Sale 1.58 8,581 13,558 881,977 Oct 23 05:00 PM Sinha Vikas See Remarks Oct 19 '23 Sale 1.58 1,232 1,947 1,171,714 Oct 23 05:00 PM Hagen Brett R Chief Accounting Officer Oct 19 '23 Sale 1.58 358 566 126,595 Oct 23 05:00 PM Brainard Diana Chief Executive Officer Oct 03 '23 Sale 1.98 1,325 2,619 890,558 Oct 05 05:00 PM Sinha Vikas See Remarks Oct 03 '23 Sale 1.98 755 1,492 1,172,946 Oct 05 05:00 PM Hagen Brett R Chief Accounting Officer Oct 03 '23 Sale 1.98 222 439 126,953 Oct 05 05:00 PM Brainard Diana Chief Executive Officer Aug 18 '23 Sale 2.79 4,055 11,313 891,883 Aug 21 05:00 PM Brainard Diana Chief Executive Officer Aug 17 '23 Sale 2.50 11,361 28,351 895,938 Aug 21 05:00 PM Sinha Vikas See Remarks Aug 17 '23 Sale 2.50 10,516 26,243 1,173,701 Aug 21 05:00 PM Hagen Brett R Chief Accounting Officer Aug 17 '23 Sale 2.50 1,653 4,125 127,175 Aug 21 05:00 PM Sinha Vikas See Remarks Jul 20 '23 Sale 3.35 1,437 4,810 1,184,217 Jul 21 05:00 PM Hagen Brett R Chief Accounting Officer Jul 20 '23 Sale 3.35 342 1,145 128,828 Jul 21 05:00 PM Brainard Diana Chief Executive Officer Jul 19 '23 Sale 3.56 8,342 29,710 907,299 Jul 21 05:00 PM Sinha Vikas See Remarks Jul 19 '23 Sale 3.56 1,198 4,267 1,185,654 Jul 21 05:00 PM Hagen Brett R Chief Accounting Officer Jul 19 '23 Sale 3.56 342 1,218 129,170 Jul 21 05:00 PM Brainard Diana Chief Executive Officer Jul 05 '23 Sale 3.05 5,275 16,063 915,641 Jul 06 05:00 PM Sinha Vikas See Remarks Jul 05 '23 Sale 3.05 2,983 9,084 1,186,852 Jul 06 05:00 PM GILEAD SCIENCES, INC. 10% Owner Jun 27 '23 Buy 3.75 2,930,870 10,990,762 16,635,286 Jun 28 05:17 PM Hagen Brett R Chief Accounting Officer Jun 09 '23 Sale 5.64 5,045 28,453 129,512 Jun 13 05:00 PM Brainard Diana Chief Executive Officer May 18 '23 Sale 4.21 4,536 19,115 916,628 May 19 05:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
